359 related articles for article (PubMed ID: 29910677)
1. Propofol attenuates osteoclastogenesis by lowering RANKL/OPG ratio in mouse osteoblasts.
Lee DW; Kwon JY; Kim HK; Lee HJ; Kim ES; Kim HJ; Kim HJ; Lee HB
Int J Med Sci; 2018; 15(7):723-729. PubMed ID: 29910677
[TBL] [Abstract][Full Text] [Related]
2. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
3. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
[TBL] [Abstract][Full Text] [Related]
4. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
[TBL] [Abstract][Full Text] [Related]
5. Resolvin E1 Promotes Bone Preservation Under Inflammatory Conditions.
El Kholy K; Freire M; Chen T; Van Dyke TE
Front Immunol; 2018; 9():1300. PubMed ID: 29946319
[TBL] [Abstract][Full Text] [Related]
6. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
Cai X; Xing J; Long CL; Peng Q; Humphrey MB
J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
[TBL] [Abstract][Full Text] [Related]
7. Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis.
Ozaki Y; Koide M; Furuya Y; Ninomiya T; Yasuda H; Nakamura M; Kobayashi Y; Takahashi N; Yoshinari N; Udagawa N
PLoS One; 2017; 12(9):e0184904. PubMed ID: 28937990
[TBL] [Abstract][Full Text] [Related]
8. Osteoclast differentiation by RANKL and OPG signaling pathways.
Udagawa N; Koide M; Nakamura M; Nakamichi Y; Yamashita T; Uehara S; Kobayashi Y; Furuya Y; Yasuda H; Fukuda C; Tsuda E
J Bone Miner Metab; 2021 Jan; 39(1):19-26. PubMed ID: 33079279
[TBL] [Abstract][Full Text] [Related]
9. The synergistic effects of IL-6/IL-17A promote osteogenic differentiation by improving OPG/RANKL ratio and adhesion of MC3T3-E1 cells on hydroxyapatite.
Sritharan S; Kannan TP; Norazmi MN; Nurul AA
J Craniomaxillofac Surg; 2018 Aug; 46(8):1361-1367. PubMed ID: 29805067
[TBL] [Abstract][Full Text] [Related]
10. [Effect of Erigeron Breviscapus on the expression of OPG/RANKL/RANK in osteoblasts and pre-osteoclasts in vitro].
Liu CG; Luo QX; Ling TY; Mo YY; Cheng ZL; Huang SG; Mo H
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Dec; 33(12):1658-64. PubMed ID: 24517065
[TBL] [Abstract][Full Text] [Related]
11. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
[TBL] [Abstract][Full Text] [Related]
12. [The OPG/RANKL/RANK system and bone resorptive disease].
Liu JZ; Ji ZL; Chen SM
Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-20 differentially regulates bone mesenchymal stem cell activities in RANKL-induced osteoclastogenesis through the OPG/RANKL/RANK axis and the NF-κB, MAPK and AKT signalling pathways.
Meng B; Wu D; Cheng Y; Huang P; Liu Y; Gan L; Liu C; Cao Y
Scand J Immunol; 2020 May; 91(5):e12874. PubMed ID: 32090353
[TBL] [Abstract][Full Text] [Related]
14. Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitro.
Sato T; Watanabe K; Masuhara M; Hada N; Hakeda Y
J Bone Miner Metab; 2007; 25(1):19-27. PubMed ID: 17187190
[TBL] [Abstract][Full Text] [Related]
15. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD
J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309
[TBL] [Abstract][Full Text] [Related]
16. Pioglitazone affects the OPG/RANKL/RANK system and increase osteoclastogenesis.
Xu F; Dong Y; Huang X; Chen P; Guo F; Chen A; Huang S
Mol Med Rep; 2016 Sep; 14(3):2289-96. PubMed ID: 27430581
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D action and regulation of bone remodeling: suppression of osteoclastogenesis by the mature osteoblast.
Baldock PA; Thomas GP; Hodge JM; Baker SU; Dressel U; O'Loughlin PD; Nicholson GC; Briffa KH; Eisman JA; Gardiner EM
J Bone Miner Res; 2006 Oct; 21(10):1618-26. PubMed ID: 16995817
[TBL] [Abstract][Full Text] [Related]
18. Alteration of bone cell function by RANKL and OPG in different in vitro models.
Lin JM; Callon KE; Lin CQ; Bava U; Zheng MH; Reid IR; Cornish J
Eur J Clin Invest; 2007 May; 37(5):407-15. PubMed ID: 17461987
[TBL] [Abstract][Full Text] [Related]
19. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.
Yamamoto Y; Udagawa N; Matsuura S; Nakamichi Y; Horiuchi H; Hosoya A; Nakamura M; Ozawa H; Takaoka K; Penninger JM; Noguchi T; Takahashi N
Endocrinology; 2006 Jul; 147(7):3366-74. PubMed ID: 16627581
[TBL] [Abstract][Full Text] [Related]
20. NAMPT expression in osteoblasts controls osteoclast recruitment in alveolar bone remodeling.
Hassan B; Baroukh B; Llorens A; Lesieur J; Ribbes S; Chaussain C; Saffar JL; Gosset M
J Cell Physiol; 2018 Sep; 233(9):7402-7414. PubMed ID: 29663373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]